{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:47:09Z","timestamp":1789922829458,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer side-population (SP) represents a sub-population of stem-like cancer cells that have an important role in drug resistance due to their high expression of the ATP-binding cassette transporter ABCG2 involved in drug export. Auranofin (AF), a clinical drug of gold complex that is used in treatment of rheumatoid arthritis, has been reported inducing tumor antiproliferation. However, whether AF can impact SP cells remains unclear. Our study showed that AF caused a depletion of SP cells and a downregulation of stem cell markers, and impaired their ability to form tumor colonies in vitro and incidence to develop tumors in vivo of lung cancer cells. Reactive oxygen species (ROS) had an important role in mediating AF-induced depletion of SP cells, which could be reversed by antioxidant NAC. Further study revealed that AF could also cause ATP depletion by inhibition of glycolysis. The depletion of cellular ATP might impair the function of ABCG2 pump, leading to increased drug accumulation within the cells and thus enhancing anticancer activity of chemotherapeutic agents such as adriamycin. Synergistic effect of AF and adriamycin was demonstrated both in vitro and in vivo. Simultaneous increase of ROS and inhibition of glycolysis is a novel strategy to eliminate stem-like cancer cells. Combination of AF with adriamycin seems to be promising to enhance therapeutic effectiveness.<\/jats:p>","DOI":"10.1038\/s41419-017-0159-4","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T10:09:52Z","timestamp":1516788592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis"],"prefix":"10.1038","volume":"9","author":[{"given":"Guo-Xin","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Pan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,24]]},"reference":[{"key":"159_CR1","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","volume":"66","author":"MF Clarke","year":"2006","unstructured":"Clarke, M. F. et al. Cancer stem cells\u2014perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66, 9339\u20139344 (2006).","journal-title":"Cancer Res."},{"key":"159_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2217\/epi.09.4","volume":"1","author":"F Crea","year":"2009","unstructured":"Crea, F., Danesi, R. & Farrar, W. L. Cancer stem cell epigenetics and chemoresistance. Epigenomics 1, 63\u201379 (2009).","journal-title":"Epigenomics"},{"key":"159_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105\u2013111 (2001).","journal-title":"Nature"},{"key":"159_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0601-3","volume":"16","author":"C Gasch","year":"2017","unstructured":"Gasch, C., Ffrench, B., O\u2019Leary, J. J. & Gallagher, M. F. Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention. Mol. Cancer 16, 43 (2017).","journal-title":"Mol. Cancer"},{"key":"159_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.stem.2011.01.007","volume":"8","author":"A Golebiewska","year":"2011","unstructured":"Golebiewska, A., Brons, N. H., Bjerkvig, R. & Niclou, S. P. Critical appraisal of the side-population assay in stem cell and cancer stem cell research. Cell Stem Cell 8, 136\u2013147 (2011).","journal-title":"Cell Stem Cell"},{"key":"159_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275\u2013284 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"159_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","volume":"12","author":"N Takebe","year":"2015","unstructured":"Takebe, N. et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat. Rev. Clin. Oncol. 12, 445\u2013464 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"159_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","volume":"16","author":"V Plaks","year":"2015","unstructured":"Plaks, V., Kong, N. & Werb, Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16, 225\u2013238 (2015).","journal-title":"Cell Stem Cell"},{"key":"159_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1871520615666150716104152","volume":"16","author":"JD Kuhlmann","year":"2015","unstructured":"Kuhlmann, J. D., Hein, L., Kurth, I., Wimberger, P. & Dubrovska, A. Targeting cancer stem cells: promises and challenges. Anticancer Agents Med. Chem. 16, 38\u201358 (2015).","journal-title":"Anticancer Agents Med. Chem."},{"key":"159_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/cdd.2013.131","volume":"21","author":"PP Liu","year":"2014","unstructured":"Liu, P. P. et al. Metabolic regulation of cancer cell side-population by glucose through activation of the Akt pathway. Cell Death Differ. 21, 124\u2013135 (2014).","journal-title":"Cell Death Differ."},{"key":"159_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/stem.1273","volume":"31","author":"S Yuan","year":"2013","unstructured":"Yuan, S. et al. Effective elimination of cancer stem cells by a novel drug combination strategy. Stem Cells 31, 23\u201334 (2013).","journal-title":"Stem Cells"},{"key":"159_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mito.2015.12.007","volume":"26","author":"B Yan","year":"2016","unstructured":"Yan, B., Dong, L. & Neuzil, J. Mitochondria: an intriguing target for killing tumour-initiating cells. Mitochondrion 26, 86\u201393 (2016).","journal-title":"Mitochondrion"},{"key":"159_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1394-7","volume":"15","author":"B Yan","year":"2015","unstructured":"Yan, B. et al. Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner. BMC Cancer 15, 401 (2015).","journal-title":"BMC Cancer"},{"key":"159_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-420117-0.00001-3","volume":"122","author":"D Zhou","year":"2014","unstructured":"Zhou, D., Shao, L. & Spitz, D. R. Reactive oxygen species in normal and tumor stem cells. Adv. Cancer Res. 122, 1\u201367 (2014).","journal-title":"Adv. Cancer Res."},{"key":"159_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/cancers2020859","volume":"2","author":"AA Dayem","year":"2010","unstructured":"Dayem, A. A., Choi, H. Y., Kim, J. H. & Cho, S. G. Role of oxidative stress in stem, cancer, and cancer stem cells. Cancers 2, 859\u2013884 (2010).","journal-title":"Cancers"},{"key":"159_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2165\/00003495-198427050-00002","volume":"27","author":"M Chaffman","year":"1984","unstructured":"Chaffman, M., Brogden, R. N., Heel, R. C., Speight, T. M. & Avery, G. S. Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs 27, 378\u2013424 (1984).","journal-title":"Drugs"},{"key":"159_CR17","doi-asserted-by":"crossref","first-page":"9118","DOI":"10.18632\/oncotarget.2361","volume":"5","author":"X Chen","year":"2014","unstructured":"Chen, X. et al. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr\/Abl-dependent and -independent mechanisms. Oncotarget 5, 9118\u20139132 (2014).","journal-title":"Oncotarget"},{"key":"159_CR18","first-page":"e415","volume":"1","author":"X Chen","year":"2014","unstructured":"Chen, X., Shi, X., Wang, X. & Liu, J. Novel use of old drug: anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells. Cancer Cell Microenviron 1, e415 (2014).","journal-title":"Cancer Cell Microenviron"},{"key":"159_CR19","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-13-2033","volume":"74","author":"W Fiskus","year":"2014","unstructured":"Fiskus, W. et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 74, 2520\u20132532 (2014).","journal-title":"Cancer Res."},{"key":"159_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000082134","volume":"26","author":"P Ellis","year":"2004","unstructured":"Ellis, P. et al. SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev. Neurosci. 26, 148\u2013165 (2004).","journal-title":"Dev. Neurosci."},{"key":"159_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","volume":"61","author":"RW Robey","year":"2009","unstructured":"Robey, R. W. et al. ABCG2: a perspective. Adv. Drug Deliv. Rev. 61, 3\u201313 (2009).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"159_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1634\/stemcells.2004-0252","volume":"23","author":"H Zaehres","year":"2005","unstructured":"Zaehres, H. et al. High-efficiency RNA interference in human embryonic stem cells. Stem Cells 23, 299\u2013305 (2005).","journal-title":"Stem Cells"},{"key":"159_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13287-015-0174-2","volume":"6","author":"S Yuan","year":"2015","unstructured":"Yuan, S. et al. Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem Cell Res. Ther. 6, 198 (2015).","journal-title":"Stem Cell Res. Ther."},{"key":"159_CR24","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","volume":"25","author":"H Pelicano","year":"2006","unstructured":"Pelicano, H., Martin, D. S., Xu, R. H. & Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633\u20134646 (2006).","journal-title":"Oncogene"},{"key":"159_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.bmc.2016.01.021","volume":"24","author":"E Gazzano","year":"2016","unstructured":"Gazzano, E. et al. Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. Bioorg. Med. Chem. 24, 967\u2013975 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"159_CR26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615\u2013627 (2002).","journal-title":"Annu. Rev. Med."},{"key":"159_CR27","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983\u20133988 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"159_CR28","first-page":"5821","volume":"63","author":"SK Singh","year":"2003","unstructured":"Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821\u20135828 (2003).","journal-title":"Cancer Res."},{"key":"159_CR29","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1158\/0008-5472.CAN-06-3557","volume":"67","author":"MM Ho","year":"2007","unstructured":"Ho, M. M., Ng, A. V., Lam, S. & Hung, J. Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827\u20134833 (2007).","journal-title":"Cancer Res."},{"key":"159_CR30","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","volume":"67","author":"C Li","year":"2007","unstructured":"Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030\u20131037 (2007).","journal-title":"Cancer Res."},{"key":"159_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645\u2013648 (1994).","journal-title":"Nature"},{"key":"159_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2017.03.008","volume":"396","author":"Y Li","year":"2017","unstructured":"Li, Y., Atkinson, K. & Zhang, T. Combination of chemotherapy and cancer stem cell targeting agents: preclinical and clinical studies. Cancer Lett. 396, 103\u2013109 (2017).","journal-title":"Cancer Lett."},{"key":"159_CR33","doi-asserted-by":"publisher","first-page":"e2887","DOI":"10.1038\/cddis.2017.272","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells. Cell Death Dis. 8, e2887 (2017).","journal-title":"Cell Death Dis."},{"key":"159_CR34","doi-asserted-by":"publisher","first-page":"e1191","DOI":"10.1038\/cddis.2014.132","volume":"5","author":"C Fan","year":"2014","unstructured":"Fan, C. et al. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis. 5, e1191 (2014).","journal-title":"Cell Death Dis."},{"key":"159_CR35","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1158\/1535-7163.MCT-12-0968","volume":"12","author":"ZY Pessetto","year":"2013","unstructured":"Pessetto, Z. Y., Weir, S. J., Sethi, G., Broward, M. A. & Godwin, A. K. Drug repurposing for gastrointestinal stromal tumor. Mol. Cancer Ther. 12, 1299\u20131309 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"159_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1023\/B:CBTO.0000004952.07979.3d","volume":"19","author":"HJ Kim","year":"2003","unstructured":"Kim, H. J. et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol. Toxicol. 19, 285\u2013298 (2003).","journal-title":"Cell Biol. Toxicol."},{"key":"159_CR37","first-page":"2425","volume":"23","author":"DT Lincoln","year":"2003","unstructured":"Lincoln, D. T., Ali Emadi, E. M., Tonissen, K. F. & Clarke, F. M. The thioredoxin-thioredoxin reductase system: overexpression in human cancer. Anticancer Res. 23, 2425\u20132433 (2003).","journal-title":"Anticancer Res."},{"key":"159_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0022-2143(03)00068-4","volume":"142","author":"J Raffel","year":"2003","unstructured":"Raffel, J. et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med. 142, 46\u201351 (2003).","journal-title":"J. Lab. Clin. Med."},{"key":"159_CR39","first-page":"32","volume":"45","author":"CK Mirabelli","year":"1985","unstructured":"Mirabelli, C. K. et al. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res. 45, 32\u201339 (1985).","journal-title":"Cancer Res."},{"key":"159_CR40","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/rheumatology\/36.8.870","volume":"36","author":"A Glennas","year":"1997","unstructured":"Glennas, A. et al. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Br. J. Rheumatol. 36, 870\u2013877 (1997).","journal-title":"Br. J. Rheumatol."},{"key":"159_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","volume":"15","author":"C Roder","year":"2015","unstructured":"Roder, C. & Thomson, M. J. Auranofin: repurposing an old drug for a golden new age. Drugs Ramp. D 15, 13\u201320 (2015).","journal-title":"Drugs Ramp. D"},{"key":"159_CR42","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/nature07733","volume":"458","author":"M Diehn","year":"2009","unstructured":"Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780\u2013783 (2009).","journal-title":"Nature"},{"key":"159_CR43","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/0008-5472.CAN-11-1674","volume":"72","author":"Y Zhou","year":"2012","unstructured":"Zhou, Y. et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res. 72, 304\u2013314 (2012).","journal-title":"Cancer Res."},{"key":"159_CR44","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley, D. B. & Johnston, P. G. Molecular mechanisms of drug resistance. J. Pathol. 205, 275\u2013292 (2005).","journal-title":"J. Pathol."},{"key":"159_CR45","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1084\/jem.183.4.1797","volume":"183","author":"MA Goodell","year":"1996","unstructured":"Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. & Mulligan, R. C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183, 1797\u20131806 (1996).","journal-title":"J. Exp. Med."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0159-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T06:34:47Z","timestamp":1671518087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0159-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,24]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1038\/s41419-017-0159-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,24]]},"assertion":[{"value":"23 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"89"}}